ChromaDex Corporation (CDXC) financial statements (2020 and earlier)

Company profile

Business Address 10900 WILSHIRE BLVD
LOS ANGELES, CA 90024
State of Incorp. DE
Fiscal Year End December 31
SIC 2833 - Medicinal Chemicals and Botanical Products (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments19192019232833
Cash and cash equivalents19192019232833
Receivables2665555
Inventory, net of allowances, customer advances and progress billings1210119877
Inventory1210119877
Contract with customer, asset 000 0 
Other undisclosed current assets1211111
Total current assets:34363835374146
Noncurrent Assets
Operating lease, right-of-use asset111 
Property, plant and equipment4444444
Intangible assets, net (including goodwill)1111222
Intangible assets, net (excluding goodwill)1111222
Deposits noncurrent assets    000
Other noncurrent assets11110  
Other undisclosed noncurrent assets   1   
Total noncurrent assets:7777666
TOTAL ASSETS:40434542424752
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities14101314141210
Accounts payable1069101097
Accrued liabilities4445444
Debt1111 000
Deferred rent credit     00
Deferred revenue and credits0
Other undisclosed current liabilities0001000
Total current liabilities:15112416141311
Noncurrent Liabilities
Long-term debt and lease obligation111 000
Finance lease, liability000 
Capital lease obligations000
Operating lease, liability111 
Liabilities, other than long-term debt444 000
Deferred revenue and credits0
Deferred revenue444 
Deferred rent credit     00
Other undisclosed noncurrent liabilities   50  
Total noncurrent liabilities:5555111
Total liabilities:20162921151412
Stockholders' equity
Stockholders' equity attributable to parent20271521273341
Common stock0000000
Additional paid in capital142140121119117115113
Accumulated deficit(122)(113)(106)(98)(90)(82)(73)
Total stockholders' equity:20271521273341
TOTAL LIABILITIES AND EQUITY:40434542424752

Income statement (P&L) ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Revenues13121110988
Revenue from related parties2221 10
Cost of revenue(6)(5)(5)(5)(4)(4)(4)
Gross profit:7765544
Operating expenses(16)(14)(13)(14)(13)(13)(12)
Operating loss:(9)(7)(7)(8)(8)(9)(8)
Nonoperating income (expense)0(0)(1)00(0)(0)
Other nonoperating expense      (0)
Interest and debt expense0(0)(1) 0(0)(0)
Net loss:(9)(8)(8)(8)(8)(9)(8)
Other undisclosed net income (loss) attributable to parent(0)01 (0)00
Net loss available to common stockholders, diluted:(9)(7)(8)(8)(8)(9)(8)

Comprehensive Income ($ in millions)

12/31/2019
Q4
9/30/2019
Q3
6/30/2019
Q2
3/31/2019
Q1
12/31/2018
Q4
9/30/2018
Q3
6/30/2018
Q2
Net loss:(9)(8)(8)(8)(8)(9)(8)
Comprehensive loss, net of tax, attributable to parent:(9)(8)(8)(8)(8)(9)(8)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: